RBOT vs. INGN, LAKE, NTRB, CLGN, MLSS, APT, COCH, LFWD, POAI, and HSCS
Should you be buying Vicarious Surgical stock or one of its competitors? The main competitors of Vicarious Surgical include Inogen (INGN), Lakeland Industries (LAKE), Nutriband (NTRB), CollPlant Biotechnologies (CLGN), Milestone Scientific (MLSS), Alpha Pro Tech (APT), Envoy Medical (COCH), ReWalk Robotics (LFWD), Predictive Oncology (POAI), and Heart Test Laboratories (HSCS). These companies are all part of the "surgical appliances & supplies" industry.
Inogen (NASDAQ:INGN) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
Vicarious Surgical has a net margin of 0.00% compared to Vicarious Surgical's net margin of -30.07%. Vicarious Surgical's return on equity of -42.87% beat Inogen's return on equity.
89.9% of Inogen shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 1.0% of Inogen shares are owned by company insiders. Comparatively, 11.7% of Vicarious Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Inogen has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Vicarious Surgical has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
In the previous week, Vicarious Surgical had 4 more articles in the media than Inogen. MarketBeat recorded 4 mentions for Vicarious Surgical and 0 mentions for Inogen. Vicarious Surgical's average media sentiment score of 0.00 beat Inogen's score of -1.00 indicating that Inogen is being referred to more favorably in the media.
Inogen received 378 more outperform votes than Vicarious Surgical when rated by MarketBeat users. Likewise, 70.44% of users gave Inogen an outperform vote while only 38.10% of users gave Vicarious Surgical an outperform vote.
Vicarious Surgical has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.
Inogen currently has a consensus price target of $7.00, indicating a potential downside of 17.26%. Vicarious Surgical has a consensus price target of $0.67, indicating a potential upside of 87.90%. Given Inogen's higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Inogen.
Summary
Inogen and Vicarious Surgical tied by winning 8 of the 16 factors compared between the two stocks.
Get Vicarious Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RBOT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vicarious Surgical Competitors List
Related Companies and Tools
